"id","uuid:ID","label","rationale","name","description","instanceType"
"StudyDesign_1","22a64e51-6df8-4798-a006-39799dfe1598","","The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated.","Study Design 1","The main design for the study","StudyDesign"
